Protara Therapeutics (TARA) Free Cash Flow (2013 - 2026)

Protara Therapeutics' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$21.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 44.63% year-over-year to -$21.3 million; the TTM figure through Mar 2026 stood at -$63.0 million (down 56.85% YoY), while the FY2025 annual figure was -$56.5 million, down 57.39% from the prior year.
• Free Cash Flow was -$21.3 million for Q1 2026 at Protara Therapeutics, down from -$17.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.0 million in Q4 2022 to a low of -$21.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$10.5 million across 5 years, with a median of -$9.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 47.52% in 2022, then slumped 82.97% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$5.0 million in 2022, then plunged by 72.89% to -$8.7 million in 2023, then dropped by 6.99% to -$9.3 million in 2024, then plunged by 82.36% to -$17.0 million in 2025, then slipped by 25.74% to -$21.3 million in 2026.
• The last three Free Cash Flow figures came in at -$21.3 million (Q1 2026), -$17.0 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.